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Abstract 
BACKGROUND Inhibition of transcription factor nuclear factor-kappa B (NFκB) is beneficial in 
various models of hypertension and renal disease. We hypothesized first that NFκB inhibition 
during renal development ameliorates hereditary hypertensive renal disease and next whether this 
was mediated via suppression of peroxisome proliferator-activated receptor (PPAR) γ coactivator 
1α.   
METHODS & RESULTS Prior to development of renal injury in Fawn-Hooded Hypertensive (FHH) 
rats, a model of hypertension, glomerular hyperfiltration, and progressive renal injury, NFkB 
activity, measured by nuclear protein expression of NFkB subunit p65, was enhanced twofold in 
2d-old male and female FHH kidneys as compared to normotensive WKY rats (p<0.05). Treating 
FHH dams with PDTC, an NFκB inhibitor, from 2wk before birth to 4wk after birth diminished NFkB 
activity in 2d-FHH offspring to 2d-WKY levels (p<0.01). Perinatal PDTC reduced systolic blood 
pressure from 20wk onwards by on average 25 mmHg (p<0.001) and ameliorated proteinuria 
(P<0.05) and glomerulosclerosis (p<0.05). In kidneys of 2d, 2wk and adult offspring of PDTC-
treated FHH dams, PPARγ coactivator 1α was induced on average by 67% (qPCR) suggesting 
that suppression of this factor by NFkB could be involved in renal damage. Follow-up experiments 
with perinatal pioglitazone, a PPARγ agonist, failed to confer persistent antihypertensive or 
renoprotective effects.  
CONCLUSIONS perinatal inhibition of enhanced active renal NFκB in 2d FHH had persistent 
antihypertensive and renoprotective effects. However, this was not the case for PPARγ stimulation. 
NFkB stimulation is therefore involved in renal damage in the FHH model of proteinuric renal 
disease by pathways other than via PPARγ. 
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Introduction 
Hypertension is associated with nitric oxide (NO) deficiency and increased reactive oxygen species 
(ROS).1 ROS can activate nuclear factor-kappa B (NFκB) via redox-sensitive signal transduction. 
NFκB is as a general transcription factor for pro-inflammatory pathways.2 Systemic and renal 
inflammation has been proposed to be an underlying mechanism which drives both hypertension 
development and renal injury.3 
 
Both inflammation and upregulation of NFκB activation are already present in kidneys of 3-wk-old 
pre-hypertensive spontaneously hypertensive rats (SHR), and NFκB inhibition can prevent the 
development of hypertension.4 Previously, we found in SHR that perinatal interventions, which 
manipulate the NO/ROS balance, can alleviate the development of hypertension in later life.5-7 
Therefore, it is conceivable that inhibiting NFκB sensitive pro-inflammatory pathways suppresses 
or prevents development of the hypertensive phenotype. Indeed, we found that perinatal treatment 
with an NFκB inhibitor (Pyrrolidine Di Thio Carbamate, PDTC) to SHR dams during pregnancy and 
lactation, abrogated development of hypertension in both female and male offspring, and lowered 
urinary excretion of lipid peroxides long after treatment was stopped.8 
 
In the current study we used the Fawn-Hooded Hypertensive rat (FHH), in order to extend these 
observations beyond the SHR model. The FHH is a genetic model of hypertension with 
progressive renal injury characterized by mild systemic hypertension, marked proteinuria and 
glomerulosclerosis (GS).9-11 Early initiation of anti-hypertensive treatment protects the FHH kidney 
more effectively than late initiation despite a similar anti-hypertensive effect.12 Perinatal 
molsidomine, a tolerance-free NO donor, persistently decreased blood pressure and ameliorated 
renal injury in male and female FHH offspring.13  
 
We hypothesized that NFκB activation is an early event that precedes development of 
hypertension and renal injury in FHH, and that perinatal inhibition of NFκB with PDTC ameliorates 
hypertension and is renoprotective in male and female FHH offspring. First, we studied NFκB 
activation in newborn FHH as well as direct and long-term effects on development of hypertension 
and renal damage of perinatal treatment with PDTC in female and male FHH offspring. Next, 
microarray studies were employed to screen the genome in the kidneys of newborn, young and 
adult FHH for genes persistently regulated in response to perinatal NFkB inhibition. Finally, since 
this analysis revealed that peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) 
gene expression was consistently increased in both genders and at all ages during and after 
perinatal PDTC treatment, we investigated the effects of perinatal treatment of FHH with the 
peroxisome proliferator-activated receptor-γ (PPARγ) agonist, pioglitazone on blood pressure and 
renal damage (proteinuria, histology) on male and female offspring. 
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Methods 
Animals  
Fawn-Hooded Hypertensive rats (FHH) were housed at 22oC, humidity 60% and exposed to a 12 h 
light/dark cycle. FHH rats were obtained from our own colony, which was derived from the original 
colony at Erasmus University Rotterdam (FHH/EUR) maintained by Dr. A. Provoost. Normotensive 
Wistar-Kyoto (WKY) rats (Harlan-Olac Oxon, UK) were used as breeders exclusively to provide 
additional control pups for NFκB activity as measured by p65 levels. Sentinel animals were housed 
under the same conditions and regularly monitored for infection by nematodes and pathogenic 
bacteria and antibodies for rodent viral pathogens (International Council for Laboratory Animal 
Science, Nijmegen, Netherlands). The Utrecht University Board for studies in experimental animals 
approved the both PDTC and Pioglitazone protocols. 
 
Treatment protocol, chronic follow up and terminal protocol  
PDTC: From day 7 of gestation, dams and their offspring received either tap water (FHH con) or 
PDTC in drinking water (150 mg/L) until 4 wk of age (FHH PDTC). At 2d of age litters were culled 
to a maximum of 8 pups/litter and at 2wk of age to a maximum of 6 pups/litter in order to 
standardize drug intake during lactation. Kidneys of culled pups were used for renal NFκB activity 
and NFκB-sensitive gene expression studies (see below). Age and sex-matched WKY pups were 
also sacrificed at the same age for measurement of renal NFκB activity. In each subgroup (FHH or 
WKY, male or female, 2d or 2wk) 5 pups were used from 5 different litters. The remaining FHH 
pups were weaned at 4wk and used for chronic follow-up until 36wk in males and 42wk in females 
(see protocol below).  
 
Pioglitazone: During the study with pioglitazone we followed the same treatment protocol. Starting 
at day 7 of gestation and until 4wk of age, FHH dams and their offspring received powdered chow 
(FHH Con) or pioglitazone (10 mg/kg body weight of the dam; FHH Pio) mixed with the powdered 
chow. At 2d of age litters were culled to a maximum of 8 pups/litter and at 2wk of age to a 
maximum of 6 pups/litter in order to standardize pioglitazone intake during lactation. Livers of 
culled pups at those two ages were used for PPARγ-sensitive gene expression (see below). The 
remaining FHH pups were weaned at 4wk and used for chronic follow-up until 42wk (see protocol 
below).  
 
At 10wk of age 10 FHH Con and 10 FHH Pio rats were used for glomerular counting, as described 
below. Standard protocols and procedures for sample collection were followed during the terminal 
experiments with the remaining FHH Con (n=14) and FHH Pio (n=15) male and female rats at 
42wk of age as described below. 
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Renal NFκB activity in pups: Whole snap-frozen kidneys from male and female FHH and WKY 
pups (2d and 2wk) were homogenized and the extracts were isolated using the Nuclear Extract Kit 
(Active Motif, Rixensart, Belgium) according to the protocol of the supplier. Concentration of protein 
extracts was determined by the Bradford method (BioRad Laboratories, Veenendaal, Netherlands). 
The NFκB component p65 was measured using TransAM™ NFκB p65 (Active Motif). A dilution 
range of recombinant NFκB p65 protein (Active Motif) was used to quantify p65 in the samples. To 
confirm linearity of the dilution range (correlation r2=0.99), the positive control cell extract included 
in the TransAmTM kit and several random samples were also diluted. All samples were measured in 
duplicate. The relative p65 content in nuclear extract was determined by comparing the p65 to 
protein concentration ratio of the same sample.  
 
Chronic follow-up: Systolic blood pressure (SBP) was measured regularly from 4wk of age by tail-
cuff. After SBP measurement rats were placed in metabolism cages without food for 24h, but with 
free access to tap water with 2% glucose, for determination of urinary excretion of protein, 
measured with Coomassie blue (Bradford).14 In the PDTC experiment female offspring were 
studied till 42wk and male offspring till 36wk. Females were followed 6wk longer because male 
FHH generally develop proteinuria sooner than female FHH.13 In the Pio experiment all offspring 
were studied till 42wk.  
 
Terminal protocol: On the day of the experiment surgery was performed as described.15-17 In short, 
rats from the PDTC experiment were anesthetized with intraperitoneal pentobarbital sodium 60 
mg/kg body weight. Rats from the Pioglitazone experiment were anesthetized through inhalation of 
isoflurane 2%.16 This discrepancy was dictated by altered ethical board requirements. Renal 
function was assessed through p-amino hippuric acid (PAH) and inulin clearances. We used PAH 
clearance to determine the renal plasma flow (RPF) and inulin clearance to determine glomerular 
filtration rate (GFR).13,16 RBF was calculated as RPF/(1-hematocrit). 
  
Microarray screening for genes in the kidney responsive to NFkB inhibition 
Detailed methodology for the microarray approach can be found in the “Supplementary Data”. 
Kidneys from 2 days, 2 weeks and adult FHH of both genders were used (n=5/group). Data 
processing was performed as described.18 The microarray data set was submitted as MIAME 
through NCBI's Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under accession 
number GSE57066. 
 
Real-time quantitative PCR 
To determine the direct effects of maternal treatment with a NFκB inhibitor or a PPARγ agonist on 
mRNA expression of NFκB- or PPARγ-target genes, RNA was isolated from kidney and liver of 2d 
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and 2wk old offspring, reverse transcribed to cDNA and quantified using real-time quantitative PCR 
(qPCR). Real-Time qPCR was performed on a ViiA™ 7 Real-Time PCR System (Applied 
Biosystems, Foster City, CA). The following TaqMan® Gene Expression Assays (Applied 
Biosystems) were used: NFκB-target genes: PGC-1α (Rn01453111_m1), PPARγ-target genes: 
Adiponectin (Rn00595250_m1), Sirtuin 6 (Rn01408250_g1), Foxo-1 (Rn01494868_m1) and CISD-
1 (Rn01429087_m1); and housekeeping genes: ß-actin (Rn00667869_m1) and calnexin 
(Rn00596877_m1). Reactions were carried out in duplicate. Cycle time (Ct) values for genes of 
interest were normalized for mean Ct-values of Calnexin and β-actin, which we previously 
determined to be the two most stable housekeeping genes across all groups using Normfinder 
(http://moma.dk/normfinder-software) and GeNorm (http://medgen.ugent.be/~jvdesomp/genorm/), 
and expressed using the ΔΔCt-method. Hence, steady state mRNA levels in treated FHH were 
expressed as % change relative to age- and gender-matched control FHH. 
 
Morphology 
At the end of each terminal experiment the right kidney was harvested, blotted dry, weighed, snap 
frozen and stored at -80oC. Subsequently, left kidney preservation was done as described by Black 
et al.19 Heparin sodium (1 unit heparin/gram body weight), to prevent clotting, and papaverine 
hydrochloride (1.2 mg/rat), to dilate the vasculature were administered via femoral artery. After 
approximately 3 min the abdominal aorta was exposed and tied off above the left renal artery. 
Then the kidney was perfused in situ with saline before fixation with 2.5% glutaraldehyde (w/v) in 
0.1M phosphate buffer (pH 7.4) at a pressure of 10 mmHg above measured MAP for 
approximately 3 min, excised, de-capsulated, and placed in 4% buffered formaldehyde. 
Paraffin sections were stained with periodic acid-Schiff. Glomeruli were counted at magnification 
50x, by applying a grid on randomly chosen fields, and expressed as number of glomeruli/mm3 (n), 
calculated by the formula n=G/(F x A x (D+T)), were G is the number glomeruli counted, F the 
number of fields counted, A the grid area, D, the average glomerular tuft diameter, and T the 
section thickness (0.004mm).20 All glomeruli were counted, irrespective of any sign of injury. Fifty 
glomeruli were scored for the presence of sclerotic lesions.21 We differentiated full sclerotic and 
partial sclerotic glomeruli and the sum of these two (sum). Glomerular and tubulo-interstitial ED-1-
antigen-positive monocytes/macrophages were determined as described.14 Paraffin sections (3 
m) of formaldehyde-fixed kidney were deparaffinized and rehydrated. Incubation with the ED-1 
mouse monoclonal antibody (Serotec/Camon, Wiesbaden, Germany) demonstrated 
monocytes/macrophages. After application of ED-1 (dilution 1: 2500 in PBS containing 5% BSA, 
0.4% sodium azide) to the slides at 22 oC for one hour, bound antibody was detected by the DAKO 
EnVision R + System (prediluted peroxidase-dextran-conjugated goat anti-mouse antibody and 
DAB colour reaction). 
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Statistics 
Values are expressed as mean ± SEM. Data were compared with unpaired t-test, one-way ANOVA 
and two-way ANOVA for repeated measurements where appropriate. The Student-Newman-Keuls 
test was used as a post-hoc test (p<0.05). Significance of differentially expressed genes between 
FHH PDTC vs. FHH Con was determined by Cyber T test using Log2 transformed and quantile 
normalized data (P<0.05). 
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Results  
Perinatal NFκB inhibition 
NFκB activity in pups: Renal levels of NFκB component p65 (mg/g protein) were increased in both 
female and male 2d-old FHH pups when compared to age and gender matched WKY pups (on 
average +50% and +200% in females and males, respectively; both P<0.01, Figure 1). Maternal 
treatment with PDTC in FHH completely prevented this increase in both females and males (both 
P<0.01). At 2w of age there were no longer differences in renal p65 levels between FHH and WKY 
and there was also no effect of PDTC in FHH. 
 
Development: All litters were carried to full gestation and litter size was not affected by PDTC (FHH 
Con: 7 ± 1 pups/litter, FHH PDTC: 7 ± 1 pups/litter). Perinatal PDTC (until 4w) resulted in a mild 
but significant decrease in body weight from 12w in females and males until sacrifice 
(Supplementary Fig. 1 and Table 1). 
 
Blood pressure, proteinuria, glomerular injury and glomerular density: Perinatal PDTC treatment 
reduced SBP at 4w in females and males and had a pronounced long-term anti-hypertensive effect 
resulting in a persistently reduced SBP by 20-30 mmHg in both female and male FHH until 
sacrifice (p<0.001, Fig. 2). Perinatal PDTC reduced proteinuria from 20w onwards in male FHH 
and at 28w and 36w in female FHH (Fig. 3) and also reduced GS at the end of the follow-up 
period. Full sclerotic glomeruli and the sum of partial and full sclerotic glomeruli were significantly 
decreased by Perinatal PDTC in both female (p<0.05) and male (p<0.001) FHH (Fig. 4). 
Glomerular macrophages were reduced by perinatal PDTC in males (1.4±0.3 vs. 7.0±1.1 ED1-
positive cells/100 glomeruli, p<0.05) as were tubulo-interstitial macrophages (0.7±0.1 vs. 2.4±0.5 
ED1-positive cells/field, p<0.05). Glomerular macrophages were practically absent in all females, 
but tubulo-interstitial macrophages were reduced by perinatal PDTC in females (0.04±0.03 vs. 
0.65±0.30 ED1-positive cells/field, p<0.05). Glomerular density was increased in male FHH PDTC 
(p<0.001, Supplementary Fig. 2) but not in female PDTC.  
 
Renal hemodynamics at the end of follow up: MAP assessed by direct femoral artery pressure 
measurements confirmed significantly reduced arterial pressure in both female and male FHH at 
the end of the follow-up period (p<0.05 and P<0.01, respectively; Table 1). Perinatal PDTC 
decreased GFR in female FHH (p<0.01) and decreased GFR, RPF and RBF in male FHH (all 
p<0.05, Table 1).  
 
Renal PDTC sensitive gene expression in pups: Differential gene expression was studied with 
Illumina Bead Arrays in whole kidney homogenates of 2d-, 2w and adult male and female FHH 
offspring of dams treated with PDTC in comparison to age and sex-matched offspring of untreated 
 9 
FHH dams (n=5/group). At 2d of age the signal on the microarray of 349 genes was different in the 
offspring of PDTC treated animals compared to matched offspring of untreated animals. This 
suggested induction of the expression of 276 genes and suppression of 73 genes in both male and 
female offspring. At 2w of age, only 9 PDTC sensitive genes were similarly differentially expressed, 
i.e. up (n = 7) and down (n = 2). None of these 9 genes were differentially expressed at 2d of age. 
The low number of PDTC-sensitive differential gene expression as studied by microarray coincides 
with the absence of differences in renal NFκB component p65 at 2w (Fig. 1).  In adults, 25 PDTC 
sensitive genes were similarly differentially expressed, i.e. up (n = 18) and down (n = 7). None of 
these 25 genes were differentially expressed at 2w of age.   
 
The most consistently regulated NFκB-sensitive gene was peroxisome proliferator-activated 
receptor γ coactivator 1 α (PGC-1α) (Table 2). This gene showed increased expression during and 
after PDTC treatment, although the increase was not significant at 2wk in males. This was 
confirmed by qPCR, although in this case the difference was not significant at 2d (Table 2). A 
selection of other NFκB-sensitive genes, grouped according to function, is listed in Supplementary 
Table 1. Functional groups include Regulation of NFκB (Nkiras1), insulin-like growth factors (IGF2 
and IGFbp3), angiogenesis and nitric oxide (VEGF, Endothelin B receptor) and nephrogenesis 
(Nidogen1, Notch1, and Nephrin). Many of the other differentially expressed genes were related to 
cell-cell communication and extracellular matrix. Note that practically all these genes were 
consistently differentially upregulated by NFκB inhibition at 2d of age. Notably, deoxyribonuclease 
1 (Dnase1) was markedly down-regulated. 
 
Perinatal PPARγ stimulation 
Hepatic PPARγ activity in pups: The liver is the canonical target of PPARγ.22,23 Hepatic mRNA 
expression of PPARγ downstream genes showed increased expression of CSD-1 and SIRT-6 
genes at 2d-old FHH rats perinatally treated with Pio compared with age-matched FHH control 
rats. At 2wk the pattern shifted and we found decreased expression of AdipoQ and FOXO-1 genes 
after perinatal treatment with Pio (Table 3). 
 
Development: All litters were carried to full gestation and litter size was not affected by perinatal 
Pio (FHH Con: 9 ± 1 pups/litter, FHH Pio 10 ± 1 pups/litter). Perinatal Pio resulted in no change in 
body weight in female offspring but a significant and persistent decrease in body weight from 24wk 
in male offspring (Supplementary Fig. 3). 
 
Blood pressure, proteinuria, glomerular injury and glomerular density: Perinatal Pio treatment 
reduced SBP at 4w in females and males. However, there was no persistent long-term anti-
hypertensive effect (Supplementary Fig. 4). Perinatal Pio had no significant effects on proteinuria in 
 10 
either female or male FHH (Supplementary Fig. 5), nor was there a reduction in GS in female or 
male Pio offspring at 42w (Supplementary Fig. 6). Glomerular density at 10w and 42w was 
unaffected by perinatal Pio (Supplementary Fig. 7).  
 
Renal hemodynamics at the end of follow up: MAP was also not significantly affected at the end of 
the follow-up period (Table 4). Perinatal Pio had no effect on GFR, RPF and RBF in female FHH 
but decreased GFR, RPF and RBF in male FHH (all p<0.05, Table 4). RVR was unchanged in 
FHH Pio females but increased in FHH Pio males (P<0.05). Note that the FHH Con data in Table 4 
differ slightly from those in Table 1, primarily due to differences in the anaesthetic regimen.  
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Discussion 
The present study addressed the question whether the previously observed induction of the pro-
inflammatory transcription factor NFkB in the early life of the SHR was also present in the FHH, 
whether inhibiting NFkB in the perinatal situation attenuated the hypertension and renal damage in 
the FHH and whether this was related to depressed PPARγ. In the FHH, NFkB is induced early in 
life and perinatal inhibition of NFkB with PDTC indeed ameliorated the hypertension and renal 
injury. Gene expression analysis of the kidney cortex revealed PPARγ depression as a potential 
mechanism of NFkB mediated hypertension and renal injury in the offspring. Despite sex specific 
alterations in renal hemodynamics, perinatal administration of a PPARγ agonist did not ameliorate 
hypertension and renal damage.  
 
Activation of redox sensitive transcription factor NFκB is associated with hypertension, with renal 
injury or both2 Moreover, inhibition of NFκB with PDTC can prevent or ameliorate both 
hypertension and renal injury in many models.4,24-28 Previously, we documented that perinatal 
interventions affecting the redox balance can ameliorate hypertension in SHR.5,6,29,30 We also 
documented that in FHH, a model of hypertensive renal injury 9-11 perinatal administration of an NO 
donor ameliorates hypertension and renal injury.13 In the current study, we first addressed the 
question whether NFκB is already activated during nephrogenesis in the FHH model and whether 
such activation plays a role in subsequent renal disease and hypertension. We could indeed 
demonstrate activation of NFκB in kidneys of newborn FHH, by increased levels of p65, a 
component of active NFκB.31 Activation of NFκB was not measured in adult rat because we probed 
effects relating to development not injury. Moreover, glomerular density was substantially 
increased in adult male FHH PDTC as compared to FHH Con. Perinatal NFκB inhibition 
persistently ameliorated the development of hypertension and proteinuria in both female and male 
FHH. At the end of the study GFR and GS were both reduced, suggesting persistent amelioration 
of hyperfiltration by Perinatal PDTC. In the FHH rat, prone as it is to hyperfiltration, 9,11,13 a similar 
hemodynamic response was observed after perinatal administration of a NO donor.13 Therefore, in 
this model of hereditary hypertension associated renal injury, early life NFkB activation seems 
pivotal to develop hypertension and renal injury. These initial results support a role for persistent 
alterations in hemodynamics after perinatal PDTC in FHH. Note that in SHR, a strain with 
increased RVR,15,17 perinatal PDTC did not significantly affect GFR or RVR in either female or 
male offspring.8 
 
Proteinuria was ameliorated by perinatal PDTC in conjunction with a significant blood pressure 
reduction. Moreover, development of glomerular sclerosis was clearly reduced by perinatal PDTC 
treatment, suggesting that the less pronounced incline in proteinuria observed in FHH PDTC, 
represents less progressive renal injury. In FHH controls RBF and GFR were positively correlated 
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with sclerosis.13 Probably this illustrates low preglomerular resistance in the FHH strain, resulting in 
glomerular hypertension, and consequently glomerular hyperperfusion, hyperfiltration and injury. 
Our current findings are compatible with the idea that perinatally inhibiting the transcription factor 
NFκB can prevent the development of glomerular hypertension by increasing afferent arteriolar 
resistance (since both GFR and RBF decrease). The reduction in macrophage infiltration was 
probably secondary to the reduction in glomerular proteinuria.13 That said, the other possibility is 
that non-hemodynamic mechanisms related to activation of NFkB early in life related genes are 
responsible for the hypertension and renal damage in the FHH. Generally PDTC is applied as an 
NF-kappa B inhibitor. However, antioxidant effects have also been described32-34, although 
arguably these could be secondary to NF-kappa B inhibition. More specific “off-target” effects 
include Nrf2 activation leading to induction of glutamate cysteine ligase modulatory gene 
expression35 and stromelysin expression via a tyrosine kinase-AP-1 pathway.36 Therefore, we feel 
that perinatal targeting of NF-kappa B by PDTC in our studies in SHR8 and FHH (this study) should 
be seen as proof of principle experiments in models of genetically programmed hypertension (SHR 
& FHH) and renal injury (FHH), and certainly not as a direct incentive to apply PDTC in the 
obstetric or neonatal clinic. 
 
Because maternal treatment with the NFκB inhibitor PDTC normalised renal levels of the NFκB 
component p65, we assessed NFκB-sensitive renal gene expression in the offspring. At 2d of age, 
in the nephrogenic phase, NFκB-sensitive renal gene expression was characterized by a 
pronephrogenic and angiogenic pattern. Nephrogenesis in the rat starts at embryonic day 12 and is 
complete at about 10 days after birth.37 NFκB activity, i.e. p65 levels, and NFκB-sensitive gene 
expression are increased in the middle of this process in the FHH. Parallel with p65 levels, NFκB-
sensitive gene expression waned at 2w of age, suggesting an association between NFκB 
activation and nephrogenesis in FHH. Indeed, Nidogen1, Notch1, Nephrin and VEGF, genes that 
are known to be involved in nephrogenesis 38,39 and angiogenesis 40 were differentially expressed 
at 2d in female and male offspring. Specifically, peroxisome proliferator-activated receptor γ co-
activator 1α (PGC-1α) was differentially expressed. This transcription factor has powerful anti-
inflammatory and vasculogenic effects and is known for its stimulatory effects on all three PPAR’s: 
α, ß, and γ. 41,42 Several other groups of genes of interest were identified by this discovery 
approach. These groups included insulin signaling, and induction of a large number of genes 
related to cell-cell communication and extracellular matrix (Supplementary table 1). All in all this 
gene expression analysis emphasized the importance of angiogenesis and nephrogenic genes and 
cell-cell communication and extracellular matrix. In line with the induction of nephrogenic genes is 
the observation of ~25% increase in glomerular density in adult male FHH treated perinatally with 
PDTC. Since we previously could identify candidates for perinatal treatment in SHR using 
differential gene expression of renal homogenates,29,30 in follow-up experiments we now tested 
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whether depression of PPARγ, downstream of the transcription factor PGC-1α, could be a 
mediator of hypertension and renal injury in FHH rats. 
 
Perinatal treatment with the PPAR-γ agonist pioglitazone (Pio) did not persistently reduce arterial 
pressure, proteinuria or glomerulosclerosis in FHH suggesting that other factors downstream of 
NFκB confer renal protection. Exposure of the pups to Pio was confirmed by characteristic 
changes in hepatic gene expression after PPARγ agonists.22,23 In addition, there appeared to be a 
direct antihypertensive effect of Pio at 4wk in female and male FHH. Mild direct antihypertensive 
effects of PPARγ agonists have been reported in models of genetic or induced hypertension,43-46 
including perinatal low-protein diet.47 Moreover, the late appearance (after 5-6 months of age) of 
reduced body weight in FHH Pio males, suggested metabolic programming. Lower body weight 
and improved glucose tolerance was observed after two weeks of Pio in a murine model of 
programmed obesity.48 Interestingly, there was a reduction in hyperfiltration and hyperperfusion in 
the male, but not the female FHH at 42 weeks after Perinatal Pio. Specifically in the male FHH, 
renal hemodynamic changes reflected the changes in the PDTC treated offspring, although the 9 
mmHg decrease in MAP was not significant. The simultaneous decrease in GFR and RPF is 
compatible with an increase in afferent arteriolar resistance. Interestingly therefore is that both 
perinatal PDTC and perinatal Pio affected renal hemodynamics (although obviously this was less 
pronounced in Pio treated rats), yet only perinatal PDTC could dampen development of 
hypertension and renal injury. This suggests that hemodynamic factors may not be the crucial link 
between perinatal induction of NFkB and subsequent renal damage.  In future experiments, it 
might be interesting to further probe the PGC-1α pathway with a PPAR-ß agonist. PPAR-ß 
agonists have been shown to have antihypertensive and renoprotective effects in genetic and 
acquired models of hypertension.49,50 
 
In conclusion, these data indicate that renal NFκB expression is enhanced in 2d FHH and that this 
can be ameliorated by the NFkB inhibitor PDTC. Perinatal PDTC stimulates gene expression 
related to angiogenesis and nephrogenesis, and has persistent antihypertensive and 
renoprotective effects, coinciding with less hyperfiltration. A key downstream layer seems the 
PGC-1α pathway, yet perinatal PPARγ stimulation did not affect hypertension and renal damage. 
Interestingly, renal hemodynamics effects of perinatal PPARγ and perinatal PDTC were similar in 
male offspring. We conclude that in the FHH rat early induction of NFkB is involved in blood 
pressure regulation and glomerular damage in the offspring, yet, when we tested one of the 
downstream genes of the PGC-1α pathway, PPARγ, the findings also pointed towards non-
hemodynamic pathways for protection.  
 14 
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Figure legends 
 
Figure 1 Renal NFκB activity assessed by p65 levels in 2d- and 2w-old female and male 
FHH rats, FHH rats treated with PDTC (via their dams), and WKY rats.  
$ p<0.01 vs. WKY and ** p<0.01 vs. FHH control 
 
Figure 2  Systolic blood pressure in female and male FHH Con (open triangles) and FHH 
PDTC (closed triangles).  
* p<0.05 vs. FHH Con 
 
Figure 3  Urinary protein excretion in female and male FHH Con (open triangles) and FHH 
PDTC (closed triangles).  
* p<0.05 vs. FHH Con 
 
Figure 4  Full, partial and sum glomerular sclerosis (GS) incidences in female (panel A) and 
male (panel B) FHH. Con (white bars) and FHH PDTC (black bars). 
* p<0.05 and ** p<0.01 vs. FHH Con 
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Table 1: Renal function (left plus right kidney) in adult female and male FHH Con and FHH PDTC  
mean ± SEM, t-test 
   
 
 FHH Con FHH PDTC p-value 
Females 42wk 
final N (pups/litters) 
10/7 8/5  
Body weight, g 
Right kidney wt, g/100 g BW 
MAP, mmHg 
GFR, ml/min 
ERPF, ml/min 
Hematocrit, vol/vol 
RBF, ml/min 
RVR (MAP/RBF), units 
277 ± 4 
0.43 ± 0.01 
114 ± 3 
3.34 ± 0.20 
9.77 ± 0.90 
0.42 ± 0.01 
16.93 ± 1.63 
6.63 ± 0.66 
258 ± 5 
0.41 ± 0.01 
104 ± 2 
2.41 ± 0.11 
7.58 ± 0.60 
0.43 ± 0.01 
13.23 ± 1.03 
8.20 ± 0.68 
0.008 
NS 
0.016 
0.002 
0.068 
NS 
0.083 
NS 
Males 36wk 
final N (pups/litters) 
10/5 16/6  
Body weight, g 
Right kidney wt, g/100 g BW 
MAP, mmHg 
GFR, ml/min 
ERPF, ml/min 
Hematocrit, vol/vol 
RBF, ml/min 
RVR (MAP/RBF), units 
407 ± 5 
0.37 ± 0.01 
122 ± 2 
3.41 ± 0.14 
10.68 ± 0.68 
0.47 ± 0.01 
20.04 ± 1.34 
6.41 ± 0.54 
386 ± 4 
0.33 ± 0.01 
115 ± 2 
2.96 ± 0.15 
8.85 ± 0.42 
0.47 ± 0.01 
16.55 ± 0.67 
7.08 ± 0.01 
0.005 
0.007 
0.006 
0.047 
0.025 
NS 
0.016 
NS 
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Table 2: Differential peroxisome proliferator-activated receptor γ coactivator 1 α (PGC-1α) gene 
expression in female and male FHH PDTC versus FHH Con 
  
 
 females males 
 microarray qPCR Microarray qPCR 
 FHH PDTC / 
FHH Con 
Con PDTC FHH PDTC / 
FHH Con 
Con PDTC 
2 days 149* 100 ± 69 142 ± 65* 145* 100 ± 85 127 ± 68 
2 weeks 127* 100 ± 70 187 ± 49* 114 100 ± 111 170 ± 67* 
adults 126* 100 ± 100 236 ± 54* 139* 100 ± 86 138 ± 53* 
 
 
Differential expression was determined in the microarray by Cyber t-test and in the qPCR (% ± 
SEM) by t-test (* P<0.05 vs. age-matched FHH Con set at 100%). n=5/group 
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Table 3: Differential hepatic PPARγ target gene expression in FHH Pio versus FHH Con pups 
(pooled female and male data) 
 
 
CSD-1 SIRT-6 AdipoQ FOXO-1 
2 days 
125 ± 11* 129 ± 8* 13 ± 50 122 ± 14 
2 weeks 
96 ± 21 84 ± 15 10 ± 24* 65 ± 18* 
Group size: 2d FHH Con n = 10, 2d FHH Pio n = 10, 2w FHH Con n = 12, 2w FHH Pio n=9. 
Differential expression was determined by qPCR (% ± SEM) by t-test (*p ≤ 0.05 vs. age-matched 
FHH Con set at 100%). mean ± SEM 
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Table 4: Renal function in female and male FHH Con and FHH Pio 
 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mean ± SEM, t-test   
  
 FHH Con FHH Pio p-value 
Females 42wk 
final N (pups/litters) 
10/5 8/5  
Body weight, g 
Right kidney wt, g/100 g BW 
MAP, mmHg 
GFR, ml/min 
ERPF, ml/min 
Hematocrit, vol/vol 
RBF, ml/min 
RVR (MAP/RBF), units 
 
285 ± 5 
0.49 ± 0.02 
127 ± 5 
1.67 ± 0.24 
6.85 ± 0.86 
0.36 ± 0.01 
10.6 ± 1.4 
13.8 ± 2.2 
 
 
276 ± 5 
0.48 ± 0.01 
125 ± 3 
1.51 ± 0.15 
5.74 ± 0.45 
0.35 ± 0.01 
8.9 ± 0.7 
14.5 ± 1.3 
 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
Males 42wk 
final N (pups/litters) 
7/5 11/5  
Body weight, g 
Right kidney wt, g/100 g BW 
MAP, mmHg 
GFR, ml/min 
ERPF, ml/min 
Hematocrit, vol/vol 
RBF, ml/min 
RVR (MAP/RBF), units 
454 ± 13 
0.41 ± 0.01 
108 ± 3 
2.32 ± 0.30 
10.25 ± 1.08 
0.37 ± 0.01 
16.0 ± 1.5 
7.0 ± 0.5 
425 ± 8 
0.42 ± 0.01 
99 ± 4 
1.58 ± 0.13 
6.72 ± 0.80 
0.39 ± 0.007 
11.0 ± 1.3 
9.5 ± 0.7 
0.006 
NS 
NS 
0.024 
0.019 
NS 
0.029 
0.020 
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Figure 1 
 
 
Renal p65
 2d  2w 2d 2w
p
6
5
 c
o
n
te
n
t 
(‰
)
0
1
2
3
4 FHH Con
FHH PDTC
WKY
**
$
**
$
Females Males
 
 
 26 
Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weeks
-2 0 4 8 12 20 28 36 42
S
B
P
 (
m
m
H
g
)
90
100
110
120
130
140
150
160
170 Female FHH Con
Female FHH PDTC
Male FHH Con
Male FHH PDTC
PDTC
* * **
*
*
*
*
*
*
* * *
 27 
 
Figure 3 
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Figure 8 
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Methodology Microarray 
After the hybridization of the samples to Illumina BeadChips RatRef-12 the raw data set 
containing all probes of each BeadArray was received. Each sample consisted of 
approximately 1 million beads, interrogating about 23K unique probes encoding genes 
(n=22523), controls, housekeeping genes and negative controls (n=825). Each gene is 
probed with at least 30 beads. Before averaging the intensities of beads per probe, the 
outliers were removed, using the same approach to removing outliers as in BeadStudio. 
The removal of outliers was based on median ± 3x median absolute deviation (MAD) and 
all beads with intensities outside the area of median ± 3xMAD were removed.Outliers were 
frequent for each probe. In our hands close to 90% of the probes had outliers. Note that 
the outliers in “empty” beads, the negative controls (NC), were not removed, as they were 
considered to be background noise of the beads themselves. After removal of outliers 
(average 3 beads) the number of beads per probe averaged 39 beads. 
 
After the test, the intensities of beads per probeare averaged for further data processing. 
Before the normalization procedure, the significance of a call from a gene was detected by 
applying a detection score that is dependent on the distribution of the intensities and the 
average intensity of the gene and NC (regardless of the number of NC). In this framework 
we performed the appropriate Student’s t-testbetween the beads of a gene and the 
average intensity of all NC on the same array including testing (in)equality between two 
population variances in order to enhance reliability of the t-test. All probes with a significant 
call above the negative background were considered biologically active in the respective 
sample. 
 
The software (T4Illumina) was written to process the raw data by averaging the intensities 
and determining the call of a gene, including determining the (un)equality of variance and 
many more. This software is available at request.  
 
The averaged intensities, after removal of outliers, of the probes from all BeadArrays are 
Log2-transformed and quantile normalized. Next the arrays were grouped accordingly and 
the average intensity per group was calculated. Finally the significance of the differences 
in intensities between the groups was calculated using Cyber t-test. Cyber-T is a statistics 
program designed specifically for microarray data (http://cybert.ics.uci.edu/). The 
 35 
normalization, averaging, and statistics procedures can all be performed by the software 
FlexArray (http://gqinnovationcenter.com/services/bioinformatics/flexarray/index.aspx?l=e). 
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Supplementary Figure Legends 
 
Supplementary Figure 1. Body weight in female (circles) and male (triangles) FHH Con 
(white) and FHH PDTC (black). Mean ± SEM, two-way ANOVA repeated measures, SNK 
post-hoc test. * p<0.05 vs. FHH con 
 
Supplementary Figure 2. Glomerular density in female (panel A) and male (panel B) FHH 
Con (white bars) and FHH PDTC (black bars).Mean ± SEM, t-test. ** p<0.01 vs. FHH Con 
 
Supplementary Figure 3. Body weight in female (circles) and male (triangles) FHH Con 
(white) and FHH Pio (black). Mean ± SEM, two-way ANOVA repeated measures, SNK 
post-hoc test.* p<0.05 vs. FHH con 
 
Supplementary Figure 4. Systolic blood pressure in female (circles) and male (triangles) 
FHH Con (white)and FHH Pio (black). Mean ± SEM, two-way ANOVA repeated measures, 
SNK post-hoc test. * p<0.05 vs. FHH control 
 
Supplementary Figure 5.  Urinary protein excretion in female (circles) and male (triangles) 
FHH Con (white) and FHH Pio (black). Mean ± SEM, two-way ANOVA repeated 
measures, SNK post-hoc test. 
 
Supplementary Figure 6.  Full, partial and sum glomerular sclerosis (GS) incidences in 
female (panel A) and male (panel B) FHH. Con (white bars) and FHH Pio (black 
bars).Mean ± SEM, t-test. 
 
Supplementary Figure 7.  Glomerular density in 10w (panel A) and 42w (panel B) female 
and male FHH Con (white bars) and FHH Pio (black bars).Mean ± SEM, t-test. 
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Supplementary Table 1. Differential expression (P<0.05vs. FHH Con set at 100%) at 2 
days in the microarray. 
  FHH PDTC versus FHH Con
             - 2 days old -
Definition Symbol Females Males
Regulation of NF-kB
NFKB inhibitor interacting Ras-like 1 Nkiras1 126 122
PPAR
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha Ppargc1a 149 145
Kidney-Specific
nidogen 1 Nid1 151 168
notch 1 Notch1 134 132
nidogen 2 Nid2 129 138
nephrosis 1, congenital, Finnish type (nephrin) Nphs1 119 121
protein phosphatase 4, regulatory subunit 1 Ppp4r1 124 118
Insulin-like Growth Factors
pregnancy-associated plasma protein A Pappa 159 137
pleiomorphic adenoma gene 1 Plag1 137 129
insulin-like growth factor binding protein 3 Igfbp3 125 129
insulin-like growth factor 2 Igf2 120 118
Angiogenesis
SPARC related modular calcium binding 2 Smoc2 127 118
neuropilin 1 Nrp1; VEGF-165 125 127
vascular endothelial growth factor C Vegfc 123 127
NO-related (cGMP, Adenylate cyclase, …)
endothelin receptor type B Ednrb 202 181
RAS p21 protein activator (GTPase activating protein) 1 Rasa1 156 151
protein kinase, cGMP-dependent, type 1 Prkg1 134 135
Cd47 molecule Cd47 133 122
adenylate cyclase activating polypeptide 1 Adcyap1 130 122
A kinase (PRKA) anchor protein 13 Akap13 120 121
phosphodiesterase 9A Pde9a 85 81
Structure-Related
integrin, alpha 1 Itga1 211 173
palladin Palld 206 160
collagen, type I, alpha 2 Col1a2 157 145
fibrillin 2 Fbn2 155 147
tensin 1 Tns1 155 149
transgelin Tagln 155 125
protocadherin 17 Pcdh17 150 149
lumican Lum 148 128
adducin 3 (gamma) Add3 148 137
ARP2 actin-related protein 2 homolog (yeast) Actr2 147 129
calcium/calmodulin-dependent protein kinase II gamma Camk2g 146 133
collagen, type VIII, alpha 1 Col8a1 140 130
matrix metallopeptidase 14 (membrane-inserted) Mmp14 138 140
collagen, type XIV, alpha 1 Col14a1 131 122
Rho-associated coiled-coil containing protein kinase 2 Rock2 129 128
collagen, type V, alpha 2 Col5a2 129 128
ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 Atp2a2 127 121
collagen, type V, alpha 1 Col5a1 125 129
dynamin binding protein Dnmbp 124 125
amine oxidase, copper containing 3 (vascular adhesion protein 1) Aoc3 124 120
NCK interacting protein with SH3 domain Nckipsd 122 120
ATPase, Ca++ transporting, plasma membrane 1 Atp2b1 121 120
core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1 C1galt1 121 123
collagen, type IV, alpha 3 (Goodpasture antigen) binding protein Col4a3bp 121 120
fibulin 2 Fbln2 121 123
laminin, beta 1 Lamb1 117 126
tropomyosin 3, gamma Tpm3 116 120
prominin 1 Prom1 116 122
collagen triple helix repeat containing 1 Cthrc1 115 124
calmodulin regulated spectrin-associated protein 1 Camsap1 113 118
deoxyribonuclease I Dnase1 58 51  
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Supplementary Figure 1. 
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Supplementary Figure 2 
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Supplementary Figure 3 
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Supplementary Figure 4 
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Supplementary Figure 6 
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Supplementary Figure 7 
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